Evidence map›Paper›PMID 41896268›Full record

ArticleScientific reports2026

Adverse events following SARS-CoV-2 mRNA vaccination in norwegian adolescents.

Vilde Bergstad Larsen, Nina Gunnes, Jon Michael Gran, Jesper Dahl, Håkon Bøås, Sara Viksmoen Watle, Jacob Dag Berild, Margrethe Greve-Isdahl, Ketil Størdal, Hanne Løvdal Gulseth and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Vilde Bergstad LarsenDivision for Health Services, Norwegian Institute of Public Health, Oslo, Norway.
Nina GunnesDivision of Mental and Physical Health, Norwegian Institute of Public Health, Oslo, Norway.
Jon Michael GranOslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway.
Jesper DahlDepartment of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway.
Håkon BøåsDepartment of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway.
Sara Viksmoen WatleDepartment of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway.
Jacob Dag BerildDepartment of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway.
Margrethe Greve-IsdahlDepartment of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway.
Ketil StørdalDepartment of Pediatric Research, Institute of Clinical Medicine, University of Oslo, and Oslo University Hospital, Oslo, Norway.
Hanne Løvdal GulsethDivision of Mental and Physical Health, Norwegian Institute of Public Health, Oslo, Norway.
Øystein KarlstadDivision of Mental and Physical Health, Norwegian Institute of Public Health, Oslo, Norway.
Paz Lopez-Doriga RuizDivision of Mental and Physical Health, Norwegian Institute of Public Health, Oslo, Norway.
German TapiaDivision of Mental and Physical Health, Norwegian Institute of Public Health, Oslo, Norway. german.tapia@fhi.no.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Norwegian COVID-19 vaccination campaign of adolescents from April 2021 necessitated surveillance of potential adverse events following immunization (AEFI). In this nationwide study of 496,432 adolescents, AEFI incidence rate ratios (IRRs) after first- and second-dose SARS-CoV-2 mRNA vaccination were compared to IRRs in unvaccinated subjects, and a self-controlled case series analysis was done as a secondary analysis. Seventeen pre-selected potential AEFIs were investigated: Anaphylactic reaction, Acute appendicitis, Lymphadenopathy, Arrhythmia, Cerebrovascular events, Death, Encephalomyelitis and meningitis, Epilepsy and convulsions, Facial nerve palsy, Herpes zoster, Idiopathic thrombocytopenic purpura, Myocarditis and pericarditis, Venous thromboembolic events, Arthropathy, Guillain-Barré syndrome, IgA vasculitis, and Multisystem inflammatory syndrome in children. Most AEFI were rare among adolescents, with few cases, and there was no statistically significant increase in the incidence of AEFIs after first-dose vaccination. Increased IRRs of anaphylactic reaction, lymphadenopathy, appendicitis, and myocarditis and pericarditis were observed following second-dose vaccination.

Indexed as

COVID-19COVID-19 VaccinesSARS-CoV-2VaccinationAdolescentAnaphylaxisBNT162 VaccineFemaleGuillain-Barre SyndromeHumansIgA VasculitisIncidenceLymphatic DiseasesMaleMyocarditisNorwayBNT162 VaccineCOVID-19 VaccinesAdolescentsAdverse eventsEpidemiologyMRNA vaccine

Identifiers

PMID41896268
PMCPMC13039709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.